As foreshadowed by many in the market, The Stock Exchange of Hong Kong Limited (“HKSE”) published its consultation conclusion on 24 April 2018 allowing listing of pre-revenue Biotech companies, the listing application for which will be entertained as soon as next week starting 30 April 2018.

We have published a series on this consultation, please refer to our latest Legal Update of 6 March 2018. The present consultation conclusion also addresses weighted voting rights (WVR) and the new secondary listing concessionary route, which we will update you separately.

Downloads –